You are here

Oral Dietary Supplement for U.S. Navy Dolphins

Award Information
Agency: Department of Defense
Branch: Navy
Contract: N00014-21-9-0002
Agency Tracking Number: N182-128-0024
Amount: $1,132,082.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N182-128
Solicitation Number: 18.2
Solicitation Year: 2018
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-06-23
Award End Date (Contract End Date): 2023-06-22
Small Business Information
2867 Farragut Road
San Diego, CA 92106
United States
DUNS: 080289063
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Stephanie Venn-Watson
 (619) 993-1440
Business Contact
 Stephanie Venn-Watson
Phone: (619) 993-1440
Research Institution

The Scope of this Phase II SBIR is to assess safety, pharmacokinetics, efficacy and scaleup of four lead micronutrients (ETI-101, ETI-070, ETI-1005 and ETI-1023) that were identified during Phase I and may be advanced as novel oral supplements to protect health in aging Navy dolphins, especially in the areas of hematological, immune, and metabolic health. The Phase II Base period (24 months) will focus on in vitro and in vivo screening of our compounds using standard laboratory assays and models, as well as initial scaleup of the selected lead compound. The Phase II Option period (24 months) will focus on larger scaleup and encapsulation of the lead compound, as well as safety and efficacy field studies.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government